Showing results (41-50 of 5,175) with videos related to
Sort By:
Pageof 518
Stem Cells Translational Medicine|August 3, 2018
Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the PromiseTimothy E G Krueger, Daniel L J Thorek, Samuel R Denmeade, et al.Journal of Medicinal Chemistry|December 14, 2001
Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cellsC M Jakobsen, S R Denmeade, J T Isaacs, et al.The Prostate|July 24, 2014
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancerW Nathaniel Brennen, D Marc Rosen, Alcides Chaux, et al.Journal of the National Cancer Institute|March 8, 2007
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic diseaseSimon A Williams, Rosemina F Merchant, Elizabeth Garrett-Mayer, et al.Proteins|September 27, 2007
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compoundsPratap Singh, Simon A Williams, Meha H Shah, et al.Progress in the Chemistry of Organic Natural Products|April 2, 2021
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug DevelopmentSøren Brøgger Christensen, Henrik Toft Simonsen, Nikolai Engedal, et al.Anti-Cancer Agents in Medicinal Chemistry|March 12, 2009
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cellsS Brøgger Christensen, Dorthe Mondrup Skytte, Samuel R Denmeade, et al.Molecular Cancer Therapeutics|May 7, 2009
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cellsDonald J Vander Griend, Lizamma Antony, Susan L Dalrymple, et al.Immunotherapy|November 5, 2020
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapyW Nathaniel Brennen, Daniel L J Thorek, Wen Jiang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cellsA T Weeraratna, S L Dalrymple, J C Lamb, et al.Pageof 518